Hims & Hers Health faces lawsuits and FTC complaint: Will HIMS recover from recent losses?

Traders Union
All News
Stocks
Hims & Hers Health slides 3.05% today

Highlights

Hims and Hers Health stock faces heightened legal and regulatory risk due to multiple class action lawsuits and an FTC complaint over privacy and billing concerns.
The company recently withdrew its compounded semaglutide pill after an FDA restriction on certain ingredients and legal threats from Novo Nordisk, limiting product revenue streams.
HIMS/USD declined 3.05% today amid mixed momentum signals, with price expected to consolidate between $27.83 to $31.59 and a higher probability of upside.

Product withdrawal and litigation risk as FTC and FDA pressures mount

Hims & Hers Health is facing multiple securities class action lawsuits following a federal complaint from the FTC on July 29, 2026, which alleged deceptive privacy and billing practices such as improper handling of customer health information and hurdles in subscription cancellation, according to PR Newswire. This heightened litigation and regulatory risk has contributed to a more cautious market stance toward the company. Additionally, Hims & Hers Health recently withdrew its compounded semaglutide pill after the FDA moved to restrict specific active pharmaceutical ingredients in non-FDA-approved compounded drugs, and following legal action threats from Novo Nordisk, as reported by Pharmexec, further limiting near-term product revenue streams.

Mixed sell momentum as volatility and oscillators diverge near support

Technically, HIMS is trading below the MA-20 but above the MA-50 and MA-200, with the Ichimoku Kijun providing immediate support at $29.64. Momentum indicators show mixed signals: MACD points to strong buy momentum, while ADX remains neutral. RSI stands at 47.75, indicating a moderate sell bias. Both Stochastic RSI and Bull/Bear Power flag oversold and seller dominance on the intraday chart, while CCI confirms a sell signal. Volatility is elevated with the price sitting mid-range and a non-zero negative gap, highlighting choppy short-term conditions as oscillators and momentum readings diverge.

Bullish reversal potential as consolidation follows volatility band formation

In the short term, HIMS is expected to trade within a range of $27.83 to $31.59, establishing a typical volatility band relative to current levels. Probability analysis suggests a 68% chance of an upward move and a 32% likelihood of a downward move, skewing the scenario toward a potential bullish reversal. The base expectation is for price consolidation between immediate support and resistance. If a breakout occurs above the $31.59 upper bound, a bullish scenario could unfold, while a failure to hold above support at $29.64 may trigger further downside.

Anton Kharitonov, expert at Traders Union, notes that Hims & Hers Health faces mounting litigation and regulatory headwinds after the FTC complaint and subsequent lawsuits. He sees the technical outlook as mixed, with near-term price volatility and little clear directional bias. Risk remains elevated given the withdrawal of the compounded semaglutide product and ongoing compliance concerns. "Until the price decisively breaks above $31.59 or resolves its legal overhang, I remain defensively positioned and prefer to wait for clarity."

Earlier, analysts noted that Hims & Hers Health was maintaining a broadly supportive technical posture despite regional expansion and operational changes. The current article introduces additional risks from regulatory action and product withdrawals, making it essential for traders to monitor ongoing legal developments and potential shifts in the established volatility band.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.